To recover your password please fill in your email address
Please fill in below form to create an account with us
Title: Single arm, open label, signal seeking, phase IIa trial of the activity of larotrectinib in patients with advanced NTRK1-3 positive tumours.
|
Trial Summary: |
The aim of this MoST substudy is to assess the clinical activity of of tremelimumab in a population of patients with advanced cancer and rare or neglected disease grouped post-hoc on the basis of tumour mutational burden (TMB) score/status. |
|
Supported By: |
|
|
Eligibility: |
Participants will be enrolled in the MoST program for molecular screening and be eligible for this substudy on the basis of high or medium ordinally ranked tumour mutational burden (TMB) score/status. |
|
Registration ID: |
ACTRN12620000918921 |
|
Participation: |
National |
|
Status: |
Recruiting |
|
Activation Date: |
21/10/2020 |
|
Chairs: |
David Thomas |
|
Contact: |